β-amyloid and Oxidative Stress: Perspectives in Drug Development.

Curr Pharm Des

Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, 95125 Catania, Italy.

Published: June 2020

Alzheimer's Disease (AD) is a slow-developing neurodegenerative disorder in which the main pathogenic role has been assigned to β-amyloid protein (Aβ) that accumulates in extracellular plaques. The mechanism of action of Aβ has been deeply analyzed and several membrane structures have been identified as potential mediators of its effect. The ability of Aβ to modify neuronal activity, receptor expression, signaling pathways, mitochondrial function, and involvement of glial cells have been analyzed. In addition, extensive literature deals with the involvement of oxidative stress in Aβ effects. Herein we focus more specifically on the reciprocal regulation of Aβ, that causes oxidative stress, that favors Aβ aggregation and toxicity and negatively affects the peptide clearance. Analysis of this strict interaction may offer novel opportunities for therapeutic intervention. Both common and new molecules endowed with antioxidant properties deserve attention in this regard.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612825666191209115431DOI Listing

Publication Analysis

Top Keywords

oxidative stress
12
6
β-amyloid oxidative
4
stress perspectives
4
perspectives drug
4
drug development
4
development alzheimer's
4
alzheimer's disease
4
disease slow-developing
4
slow-developing neurodegenerative
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!